经济观察网 基于公开信息，正业生物（ZYBT.US）是一家专注于兽用疫苗研发、生产和销售的公司， 主要收入来自猪疫苗和家禽疫苗。截至2026年1月的最新数据，该公司股价和成交额出现波动，例如 2026年1月9日成交额激增230.03%，但已知信息中未提及任何计划中的重大事件（如新产品发布、临床 试验进展或资本运作）。 以上内容基于公开资料整理，不构成投资建议。 ...

股价表现：截至2026年02月13日，正业生物收盘价为0.96美元，单日跌幅4.75%。近7日（02月08日至02 月14日）区间涨跌幅为14.52%（以02月07日收盘价0.84美元为起始点），最高价触及1.19美元（02月10 日），最低价下探0.77美元（02月09日），区间振幅达50.24%。 交易情况：近7日成交量和成交额较前期放大，但整体流动性较低，02月13日换手率仅为0.03%。同期 美股大盘指数震荡，纳斯达克指数近五日跌幅2.10%，制药板块涨跌幅为1.06%。 行业关联：公司主营兽用疫苗（尤其猪疫苗），近期生猪养殖行业数据发布频繁（如傲农生物1月生猪 销售量同比增长35.36%），可能间接影响市场情绪。 来源：经济观察网 经济观察网 正业生物近7个交易日股价波动显著，区间振幅较大。公司期间通过官方渠道定期发布生猪 价格快报，更新行业数据，但未披露重大业务进展或事件。这些信息主要为行业动态更新，对股价直接 影响有限。 股票近期走势 以上内容基于公开资料整理，不构成投资建议。 ...

经济观察网 正业生物（ZYBT.OQ）近7个交易日（2026年02月05日至02月11日）股价波动显著，区间涨 跌幅达20.24%，振幅为55.95%。具体来看，股价从02月05日的0.75美元低点反弹，02月09日单日涨幅 25.00%，最高触及02月10日的1.19美元，但02月11日回落至1.01美元，当日跌幅0.98%。同期成交量和 成交额较前期有所放大，但整体流动性较低。 公司于02月11日和02月05日通过官方渠道定期发布生猪价格快报，更新外三元、内三元等生猪价格及饲 料原料数据，但未披露重大业务进展或事件。这些信息主要为行业数据更新，对股价直接影响有限。 以上内容基于公开资料整理，不构成投资建议。 近期事件 ...

Core Achievements in 2025 - The company achieved significant milestones in 2025, focusing on R&D innovation, regulatory approvals, and operational excellence to enhance competitiveness in the veterinary vaccine market [4][5] - Four new patents were granted, and ten new patent applications were filed to sustain the innovation pipeline [5] - The company received two National Category I and one National Category III New Veterinary Drug Registration Certificates, enhancing its product portfolio and market position [5] - Seven new product approval licenses were secured, expanding offerings across swine, poultry, cattle, and sheep [5] - The company established the Jilin Province Animal Vaccine Science and Technology Innovation Center with government funding of RMB800,000 [5] - The flagship product "Zhengyuanzhen" was awarded "Excellent Vaccine Product of the Year" at the 2025 China Swine Industry Glory List [6] International Market Expansion - The company submitted registration materials for poultry vaccines in Egypt, Pakistan, and Vietnam, with approvals expected in 2026 [12] - A dedicated swine health business unit was established to enhance customer engagement and support key accounts [12] Production Capabilities and Digital Transformation - The company upgraded its bacterial inactivated vaccine production line to include bacterial culture subunit vaccine capabilities [12] - Key production processes were computerized to improve manufacturing efficiency and product quality consistency [12] Strategic Outlook for 2026 - The company plans to deepen strategic customer engagement and strengthen its product portfolio with solution-based marketing [13][14] - A merger and acquisition strategy will focus on the companion animal sector to broaden the product portfolio and enhance capabilities [17] - The company aims to solidify market leadership of its core product and advance the development of new vaccines [18]

Group 1 - The article highlights significant declines in the stock prices of several Chinese concept stocks, with Triller Group experiencing the largest drop of 40.47% [1] - Other notable declines include Ping An Biopharmaceutical down 23.25%, Zhengye Technology down 21.57%, Dongyuan Global down 21.52%, and Daziran Pharmaceutical down 21.35% [1] - The trading volumes for these stocks varied, with Triller Group having a trading volume of 2.32 million, while Daziran Pharmaceutical had a volume of 0.6327 million [1]

Core Viewpoint - Chinese concept stocks experienced significant declines, with the top five losers showing steep drops in their stock prices. Group 1: Stock Performance - Libang Kitchenware (LBGJ) fell by 50.93%, closing at 0.660, with a decrease of 0.685 and a trading volume of 3.6995 million [1] - Zhengye Biological (ZYBT) dropped by 39.64%, ending at 3.000, down by 1.970, with a trading volume of 8.2297 million [1] - Reaya Electronics (RAYA) decreased by 33.05%, closing at 0.0476, down by 0.0235, with a trading volume of 3.9496 million [1] - Xiao i Robot (AIXI) saw a decline of 23.21%, closing at 1.290, down by 0.390, with a trading volume of 1.4258 million [1] - Easy Electric (EZGO) fell by 16.08%, ending at 0.1879, down by 0.0360, with a trading volume of 0.9919 million [1]

Core Viewpoint - Chinese concept stocks experienced significant declines, with Zhengye Biology leading the drop at 19.98% [1] Group 1: Stock Performance - Zhengye Biology fell by 19.98%, marking it as the largest decline among Chinese concept stocks [1] - Ming Teng International decreased by 19.53% [1] - Ango Meng dropped by 17.27% [1] - Jialishi Talent saw a decline of 16.29% [1] - Tiger Technology experienced a 15.51% decrease [1]

Group 1 - The top five gainers among Chinese concept stocks include: Mindonghong with a rise of 35.33%, Pitanium up by 21.27%, Heitong Technology increasing by 17.07%, Zhengye Biology rising 14.7%, and Mint up 14.24% [1] - Mindonghong (ORIS) closed at 0.1827 with a gain of 35.33%, translating to an increase of 0.0477 and a trading volume of 13.18 million [1] - Pitanium (PTNM) reached a price of 7.240, marking a 21.27% increase, which is an addition of 1.270 with a trading volume of 9.68 million [1] Group 2 - Heitong Technology (DKI) saw its stock price rise to 8.300, reflecting a 17.07% increase, equivalent to a gain of 1.210 and a trading volume of 4.25 million [1] - Zhengye Biology (ZYBT) closed at 10.690, with a 14.70% increase, amounting to a rise of 1.370 and a trading volume of 2.35 million [1] - Mint (MIMI) ended at 10.750, showing a 14.24% increase, which is an increase of 1.340 with a trading volume of 39.62 million [1]

Group 1 - The top five Chinese concept stocks that experienced the largest declines at closing were: 707 Cayman Holdings down 65.81%, MoBe down 33.33%, Deep Fan Lian down 23.78%, Zhengye Biology down 23.02%, and Hongyao Digital Technology down 22.76% [1][1][1] Group 2 - 707 Cayman Holdings had a latest price of 0.759 with a decline of 1.461 and a trading volume of 29.17 million [1][1][1] - MoBe's latest price was 0.0002, down by 0.0001 with a trading volume of 0.00024 million [1][1][1] - Deep Fan Lian's latest price was 0.3026, down by 0.0944 with a trading volume of 0.1519 million [1][1][1] - Zhengye Biology's latest price was 9.750, down by 2.915 with a trading volume of 4.3126 million [1][1][1] - Hongyao Digital Technology's latest price was 1.120, down by 0.330 with a trading volume of 1.3085 million [1][1][1]

Group 1 - The top five gainers among Chinese concept stocks include Luda Technology with a rise of 62.6%, Zhengye Biology with 35.31%, Xiangsong International with 31.87%, AirNet Technology with 28.77%, and Cheche Technology with 24.68% [1] - Luda Technology's latest price is 9.870, with a gain of 3.800 and a trading volume of 9.4865 million [1] - Zhengye Biology's latest price is 12.665, with a gain of 3.305 and a trading volume of 2.9232 million [1] Group 2 - Xiangsong International's latest price is 2.255, with a gain of 0.545 and a trading volume of 4.2776 million [1] - AirNet Technology's latest price is 5.550, with a gain of 1.240 and a trading volume of 2.31 million [1] - Cheche Technology's latest price is 1.1100, with a gain of 0.2197 and a trading volume of 2.9753 million [1]